NCT00031980

Cyclosporine in Treating Patients With Low Blood Counts Caused By Hematologic Cancer

Phase II Study of Cyclosporine in T-Cell Large Granular Lymphocytic Leukemia

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Alliance for Clinical Trials in Oncology · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: Cyclosporine may improve low blood counts caused by hematologic cancer. PURPOSE: Phase II trial to study the effectiveness of cyclosporine in treating patients who have low blood counts caused by hematologic cancer.

Detailed description

OBJECTIVES: * Determine the frequency of cytopenic response in patients with T-cell large granular lymphocytic leukemia treated with cyclosporine. OUTLINE: This is a multicenter study. Patients receive oral cyclosporine every 12 hours. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed every 4 months for 1 year and then every 6 months for 9 years. PROJECTED ACCRUAL: A total of 9-30 patients will be accrued for this study within 3 years.

Conditions

• Anemia
• Leukemia
• Neutropenia
• Thrombocytopenia

Interventions

Type	Name	Description
DRUG	cyclosporine

Timeline

• Start date: 2002-03-01
• Primary completion: 2005-05-01
• Completion: 2005-05-01
• First posted: 2003-01-27
• Last updated: 2016-07-06

Locations

1 site across 1 country: United States